GlaxoSmithKline PLC (GSK) Lifted to Buy at Zacks Investment Research

GlaxoSmithKline PLC (GSK) Lifted to Buy at Zacks Investment Research


The firm currently has a $44.00 target price on the pharmaceutical company's stock. Zacks Investment Research's target price indicates a potential upside of 9.24% from the stock's current price.



from Biotech News